Are Wall Street Analysts Bullish on Solventum Stock?

Wall Street analysts are currently divided on whether to be bullish on Solventum Corporation's (SOLV) stock. With a market capitalization of approximately $14.5 billion, the Minnesota-based company develops healthcare solutions through health, material, and data science. While SOLV has underperformed the broader market and the S&P 500 Index over the past year, it has outperformed both on a year-to-date basis.

In their latest Q2 FY2026 earnings report, SOLV reported a 2.2% year-over-year increase in net sales and a 9.5% increase in organic sales. The company raised its full-year growth guidance and adjusted EPS expectations, leading to a "Moderate Buy" consensus rating from analysts. However, the number of "Strong Buy" recommendations has decreased among the 16 analysts covering SOLV stock.

Price targets from Wells Fargo's Nathan Treybeck suggest a 7.7% upside potential from SOLV's current share price.